Systemic and topical corticosteroids in the treatment of ulcerative colitis
Knyazev O.V., Kagramanova A.V., Fadeeva N.A.

Moscow Clinical Scientific and Practical Center, Russia

In Russia, budesonide multimatrix (MMX®, Cortiment®) is approved for the treatment of ulcerative colitis. Budesonide is a topical corticosteroid with anti-inflammatory effects which are superior to that of many other glucocorticoids. Cortiment is formulated to release budesonide at a controlled rate throughout the colon. The paper summarizes the results of CORE I and CORE II trials which assessed the efficacy and safety of budesonide MMX in adults with mild to moderate ulcerative colitis. Budesonide MMX 9 mg was statistically significantly more effective than placebo in several patient groups. Budesonide had a better safety profile as compared with the first-generation oral corticosteroids (i.e., prednisone and prednisolone). Cortiment is highly effective in the lack of response to the treatment with 5-aminosalicylic acid.

Key words: budesonide, Cortiment, clinical remission, mucosal healing, ulcerative colitis.

For citation: Knyazev O.V., Kagramanova A.V., Fadeeva N.A. Systemic and topical corticosteroids in the treatment of ulcerative colitis // RMJ. Gastroenterology. 2016. № 11. P. 697–702.